SCHEMBL6980579

SCHEMBL6980579

O=C(N[C@H]1CCN(Cc2nc[nH]n2)C1)[C@@H]1CCCCN1c1nc2ccccc2o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.46
TSHR P16473 4/20 0.46
MAPT P10636 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 2/20 0.46
OPRK1 P41145 1/20 0.41
ELANE P08246 2/20 0.39
ALDH1A1 P00352 6/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
CHRNA7 P36544 1/20 0.37
HTR3A P46098 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SSTR5 P35346 1/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6968264 0.87 OPRK1 (0.56) LMNATSHRMAPTSMN1; SMN2HTT
SCHEMBL6978779 0.87 OPRK1 (0.56) LMNATSHRMAPTSMN1; SMN2HTT
SCHEMBL6975899 0.85 LMNA (0.49) LMNATSHRMAPTSMN1; SMN2HTT
SCHEMBL6975047 0.84 OPRK1 (0.48) LMNATSHRMAPTSMN1; SMN2HTT
SCHEMBL7086933 0.84 LMNA (0.46) LMNATSHRMAPTSMN1; SMN2HTT
SCHEMBL7084048 0.84 LMNA (0.46) LMNATSHRMAPTSMN1; SMN2HTT
SCHEMBL7083455 0.84 LMNA (0.47) LMNATSHRMAPTSMN1; SMN2HTT
SCHEMBL6966984 0.83 LMNA (0.50) LMNATSHRMAPTSMN1; SMN2HTT
SCHEMBL6974472 0.82 LMNA (0.52) LMNATSHRMAPTSMN1; SMN2HTT
SCHEMBL6967773 0.82 CXCR4 (0.47) LMNATSHRMAPTSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6562964-B1 Inhibitors of rotamase enzymes in particular FKBP-12 and FKBP-52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases or other disorders PFIZER INC 2003-05-13 US disclosed
EP-1100797-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES PFIZER LTD (GB) 2003-02-26 EP disclosed
US-6372736-B1 ENZYME INHIBITORS PFIZER INC 2002-04-16 US disclosed
EP-1100797-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES Pfizer Limited (GB) 2001-05-23 EP disclosed
WO-2000005232-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES PFIZER LIMITED (GB) 2000-02-03 WO disclosed